Loading
A phase 1/2 trial of Pembrolizumab in metastatic cancer and ovarian cancer, run by PMV Pharmaceuticals, Inc, now recruiting.
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is a phase 1/2 interventional study registered as NCT04585750 by PMV Pharmaceuticals, Inc, with 300 participants planned, started 2020-10-29 and due to reach its primary completion in 2026-12-15. Interventions recorded: rezatapopt, pembrolizumab. Conditions listed: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Pembrolizumab.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Immune checkpoint inhibitors.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Ovarian cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/